Cargando…

NQPC-5 Does high-dose methotrexate-based chemotherapy for relapsed primary CNS lymphoma increase a risk of leukoencephalopathy with prior whole brain radiotherapy?

Backgrounds: Standard care for primary central nervous system lymphoma (PCNSL) comprises high-dose (HD) methotrexate (MTX) -based chemotherapy with or without consolidation whole brain radiotherapy (WBRT). HD-MTX administration following WBRT has been suggested to increase a risk of leukoencephalopa...

Descripción completa

Detalles Bibliográficos
Autores principales: Kobayashi, Keiichi, Sasaki, Nobuyoshi, Saito, Kuniaki, Yamagishi, Yuki, Hanayama, Naomi, Nakatomi, Hirofumi, Shiokawa, Yoshiaki, Nagane, Motoo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8648221/
http://dx.doi.org/10.1093/noajnl/vdab159.083
_version_ 1784610760362557440
author Kobayashi, Keiichi
Sasaki, Nobuyoshi
Saito, Kuniaki
Yamagishi, Yuki
Hanayama, Naomi
Nakatomi, Hirofumi
Shiokawa, Yoshiaki
Nagane, Motoo
author_facet Kobayashi, Keiichi
Sasaki, Nobuyoshi
Saito, Kuniaki
Yamagishi, Yuki
Hanayama, Naomi
Nakatomi, Hirofumi
Shiokawa, Yoshiaki
Nagane, Motoo
author_sort Kobayashi, Keiichi
collection PubMed
description Backgrounds: Standard care for primary central nervous system lymphoma (PCNSL) comprises high-dose (HD) methotrexate (MTX) -based chemotherapy with or without consolidation whole brain radiotherapy (WBRT). HD-MTX administration following WBRT has been suggested to increase a risk of leukoencephalopathy. However, given that there are no other agents with efficacy similar to or better than MTX, patients with relapsed PCNSL may often be treated with regimens containing HD-MTX if the initial MTX treatment achieved a long-term complete remission. Here, we retrospectively analyzed prevalence and an extent of white mater damages in association with prior WBRT in patients with relapsed PCNSL treated with HD-MTX based therapy. Patients & methods: Among 79 patients with relapsed/refractory PCNSL in a total of 162 patients with newly-diagnosed PCNSL treated in our institution from April, 2000 to February, 2021, 35 patients were identified with evaluable KPS, MMSE, and Fazekas scale data at both baseline and follow-up periods. Of the 35 patients, 22 were treated with chemotherapy at a relapse (10 with prior WBRT, while 12 without WBRT), and were included in this preliminary study. Results: In the WBRT group (male/female: 5/5), median age was 65 years (range, 45–73), initial median KPS was 70 (40–90), and median WBRT dose was 27 Gy (23.4–40). Median progression-free survival (mPFS) was 11.8 months, and median overall survival (mOS) was not reached. In the non-WBRT group (M/F 8/4), median age 75 (62–84), initial mKPS 80 (50–90), mPFS 16.2 m, and mOS not reached. Initial KPS and MMSE score tended to be worse in WBRT group, presumably due to enrichment of patients with poorer performance status and more comorbidities. A decline in the Fazekas score was not associated with MMSE deterioration.Conclusions: The preliminary analysis was not informative enough, and further extensive imaging analysis will be exploited.
format Online
Article
Text
id pubmed-8648221
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-86482212021-12-07 NQPC-5 Does high-dose methotrexate-based chemotherapy for relapsed primary CNS lymphoma increase a risk of leukoencephalopathy with prior whole brain radiotherapy? Kobayashi, Keiichi Sasaki, Nobuyoshi Saito, Kuniaki Yamagishi, Yuki Hanayama, Naomi Nakatomi, Hirofumi Shiokawa, Yoshiaki Nagane, Motoo Neurooncol Adv Supplement Abstracts Backgrounds: Standard care for primary central nervous system lymphoma (PCNSL) comprises high-dose (HD) methotrexate (MTX) -based chemotherapy with or without consolidation whole brain radiotherapy (WBRT). HD-MTX administration following WBRT has been suggested to increase a risk of leukoencephalopathy. However, given that there are no other agents with efficacy similar to or better than MTX, patients with relapsed PCNSL may often be treated with regimens containing HD-MTX if the initial MTX treatment achieved a long-term complete remission. Here, we retrospectively analyzed prevalence and an extent of white mater damages in association with prior WBRT in patients with relapsed PCNSL treated with HD-MTX based therapy. Patients & methods: Among 79 patients with relapsed/refractory PCNSL in a total of 162 patients with newly-diagnosed PCNSL treated in our institution from April, 2000 to February, 2021, 35 patients were identified with evaluable KPS, MMSE, and Fazekas scale data at both baseline and follow-up periods. Of the 35 patients, 22 were treated with chemotherapy at a relapse (10 with prior WBRT, while 12 without WBRT), and were included in this preliminary study. Results: In the WBRT group (male/female: 5/5), median age was 65 years (range, 45–73), initial median KPS was 70 (40–90), and median WBRT dose was 27 Gy (23.4–40). Median progression-free survival (mPFS) was 11.8 months, and median overall survival (mOS) was not reached. In the non-WBRT group (M/F 8/4), median age 75 (62–84), initial mKPS 80 (50–90), mPFS 16.2 m, and mOS not reached. Initial KPS and MMSE score tended to be worse in WBRT group, presumably due to enrichment of patients with poorer performance status and more comorbidities. A decline in the Fazekas score was not associated with MMSE deterioration.Conclusions: The preliminary analysis was not informative enough, and further extensive imaging analysis will be exploited. Oxford University Press 2021-12-06 /pmc/articles/PMC8648221/ http://dx.doi.org/10.1093/noajnl/vdab159.083 Text en © The Author(s) 2021. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Supplement Abstracts
Kobayashi, Keiichi
Sasaki, Nobuyoshi
Saito, Kuniaki
Yamagishi, Yuki
Hanayama, Naomi
Nakatomi, Hirofumi
Shiokawa, Yoshiaki
Nagane, Motoo
NQPC-5 Does high-dose methotrexate-based chemotherapy for relapsed primary CNS lymphoma increase a risk of leukoencephalopathy with prior whole brain radiotherapy?
title NQPC-5 Does high-dose methotrexate-based chemotherapy for relapsed primary CNS lymphoma increase a risk of leukoencephalopathy with prior whole brain radiotherapy?
title_full NQPC-5 Does high-dose methotrexate-based chemotherapy for relapsed primary CNS lymphoma increase a risk of leukoencephalopathy with prior whole brain radiotherapy?
title_fullStr NQPC-5 Does high-dose methotrexate-based chemotherapy for relapsed primary CNS lymphoma increase a risk of leukoencephalopathy with prior whole brain radiotherapy?
title_full_unstemmed NQPC-5 Does high-dose methotrexate-based chemotherapy for relapsed primary CNS lymphoma increase a risk of leukoencephalopathy with prior whole brain radiotherapy?
title_short NQPC-5 Does high-dose methotrexate-based chemotherapy for relapsed primary CNS lymphoma increase a risk of leukoencephalopathy with prior whole brain radiotherapy?
title_sort nqpc-5 does high-dose methotrexate-based chemotherapy for relapsed primary cns lymphoma increase a risk of leukoencephalopathy with prior whole brain radiotherapy?
topic Supplement Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8648221/
http://dx.doi.org/10.1093/noajnl/vdab159.083
work_keys_str_mv AT kobayashikeiichi nqpc5doeshighdosemethotrexatebasedchemotherapyforrelapsedprimarycnslymphomaincreaseariskofleukoencephalopathywithpriorwholebrainradiotherapy
AT sasakinobuyoshi nqpc5doeshighdosemethotrexatebasedchemotherapyforrelapsedprimarycnslymphomaincreaseariskofleukoencephalopathywithpriorwholebrainradiotherapy
AT saitokuniaki nqpc5doeshighdosemethotrexatebasedchemotherapyforrelapsedprimarycnslymphomaincreaseariskofleukoencephalopathywithpriorwholebrainradiotherapy
AT yamagishiyuki nqpc5doeshighdosemethotrexatebasedchemotherapyforrelapsedprimarycnslymphomaincreaseariskofleukoencephalopathywithpriorwholebrainradiotherapy
AT hanayamanaomi nqpc5doeshighdosemethotrexatebasedchemotherapyforrelapsedprimarycnslymphomaincreaseariskofleukoencephalopathywithpriorwholebrainradiotherapy
AT nakatomihirofumi nqpc5doeshighdosemethotrexatebasedchemotherapyforrelapsedprimarycnslymphomaincreaseariskofleukoencephalopathywithpriorwholebrainradiotherapy
AT shiokawayoshiaki nqpc5doeshighdosemethotrexatebasedchemotherapyforrelapsedprimarycnslymphomaincreaseariskofleukoencephalopathywithpriorwholebrainradiotherapy
AT naganemotoo nqpc5doeshighdosemethotrexatebasedchemotherapyforrelapsedprimarycnslymphomaincreaseariskofleukoencephalopathywithpriorwholebrainradiotherapy